Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

The primary objective of this study is to evaluate the safety and tolerability of ONO-6950 across ascending multiple doses in healthy adult male and female subjects. The secondary objectives are to characterize the PK and pharmacodynamic (PD) profiles of ONO-6950 by measuring plasma concentrations of ONO-6950 and pulmonary function.

Inclusion Criteria:

• Healthy non-smoking male or female subjects (18-55 inclusive)
• Body mass index (BMI)of 10-35 kg/m2 (inclusive)
• For females; postmenopausal, non-lactating, and non-pregnant

Exclusion Criteria:

• History or presence of clinical significant disease